| Bioactivity | Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD)[1][2]. | ||||||||||||
| Invitro | FimH is a TLR4 receptor, expressed on E. coli and other Enterobacteriaceae in host with CD. The inhibition of FimH adhesion, and consequently intracellular replication of adherent-invasive E. coli in epithelial cells, may prevent establishment of a sub-mucosal infection leading to mucosal inflammation and epithelial barrier disruption[1][2]. | ||||||||||||
| Name | Sibofimloc | ||||||||||||
| CAS | 1616113-45-1 | ||||||||||||
| Formula | C35H39NO11 | ||||||||||||
| Molar Mass | 649.68 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Sibofimloc
CAS: 1616113-45-1 F: C35H39NO11 W: 649.68
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from pa
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.